• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, September 19, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

The fewer the deadlier

Bioengineer by Bioengineer
April 12, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Kyoto University / Jun-ichirou Yasunaga

Japan — A study appearing in the in Proceedings of the National Academy of Sciences gives new clues into how cancers like leukemia form from the retrovirus HTLV-1, as well as insights into the possible creation of a vaccine.

HTLV-1 is a human retrovirus that mainly infects the CD4+ T cell. Such Infections can lead to a host of immune-related diseases including leukemia. Somewhat counterintuitively, the virus thrives by remaining at very low levels in the body, which is unlike its more notorious cousin, HIV.

"HTLV-1 RNA is rarely detected in the plasma of infected individuals, and it persists by evading host immune surveillance," says Jun-ichirou Yasunaga of Kyoto University's Institute for Frontier Life and Medical Sciences, who led the study.

HTLV-1 encodes two oncogenic factors, Tax and HBZ. Besides its function as an oncoprotein, Tax also facilitates viral replication. "The precise role of Tax in pathogenesis is unknown, since it is so faintly expressed in infected cells," continues Yasunaga.

The researchers found that within populations of infected leukemic cells, only a tiny fraction — less than 3% — expressed Tax. Moreover, this expression in any given cell was transient, lasting less than 24 hours. However, while the cells that expressed Tax would change over time, more than 3% of the population would express this gene.

In fact, in vitro experiments showed that if Tax expression was suppressed in this small population, then almost all infected cells would vanish in less than a month. Furthermore, computational simulations found that it takes about five months for 90% of the infected cells to eventually express Tax. This transience is advantageous for the survival of the virus, since persistent Tax expression is associated with an immune response.

Yasunaga explains that keeping the expression of Tax limited to a small population allows the infection to flourish and prevent the infected cells from undergoing controlled death, known as apoptosis.

"There were clear differences in the gene expression between Tax-expressing and Tax-non-expressing cells. In the latter there were two populations, those with medium, and those with low levels of anti-apoptotic factors. This shows that Tax caused different degrees of sensitivity to apoptosis," he explains.

Further studies revealed that this effect on apoptosis sensitivity was found in cells with better overall survivability. Yasunaga hypothesizes that even if cells stop expressing Tax, those with medium levels of anti-apoptosis factors are more resistant to apoptosis, allowing these cells to survive.

"Transient Tax expression is a unique way through which enhances the survival and proliferation of infected cells, so it makes it a good vaccine target. Understanding its expression mechanism could be a key to new therapies," says Yasunaga.

###

The paper "Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells" appeared 22 January 2018 in the journal Proceedings of the National Academy of Sciences of the United States of America, with doi: 10.1073/pnas.1715724115.

About Kyoto University

Kyoto University is one of Japan and Asia's premier research institutions, founded in 1897 and responsible for producing numerous Nobel laureates and winners of other prestigious international prizes. A broad curriculum across the arts and sciences at both undergraduate and graduate levels is complemented by numerous research centers, as well as facilities and offices around Japan and the world. For more information please see: http://www.kyoto-u.ac.jp/en

Media Contact

Raymond Kunikane Terhune
[email protected]
81-757-535-728
@KyotoU_News

http://www.kyoto-u.ac.jp/en

Related Journal Article

http://dx.doi.org/10.1073/pnas.1715724115

Share12Tweet8Share2ShareShareShare2

Related Posts

Tirzepatide Enhances Blood Sugar Regulation in Adolescents with Type 2 Diabetes Unresponsive to Current Treatments (SURPASS-PEDS Trial)

September 18, 2025

Texas A&M Researchers Develop Innovative Cryopreservation Technique to Stop Organ Cracking

September 18, 2025

Optimizing Geriatric Care: Staff Insights on Patient Mobilization

September 18, 2025

Researchers Pinpoint Potential Therapeutic Targets in Pediatric Germ Cell Tumors

September 18, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    155 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tirzepatide Enhances Blood Sugar Regulation in Adolescents with Type 2 Diabetes Unresponsive to Current Treatments (SURPASS-PEDS Trial)

Emerging Research Links Microplastics to Potential Risks for Bone Health

Early Universe Galaxies Unveil Hidden Dark Matter Maps

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.